Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Elliott Hayden"'
Publikováno v:
G3: Genes, Genomes, Genetics, Vol 10, Iss 6, Pp 1843-1852 (2020)
FUS is a nucleic acid binding protein that, when mutated, cause a subset of familial amyotrophic lateral sclerosis (ALS). Expression of FUS in yeast recapitulates several pathological features of the disease-causing mutant proteins, including nuclear
Externí odkaz:
https://doaj.org/article/cb9f4e81996a406997ba1f39144ca93a
Mutations in Fused in Sarcoma (FUS), an RNA binding protein that functions in multiple steps in gene expression regulation and RNA processing, are known to cause familial amyotrophic lateral sclerosis (ALS). Since this discovery, mutations in several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ceccf15bf16d2ca278db4c22697b750
https://doi.org/10.21203/rs.3.rs-437201/v1
https://doi.org/10.21203/rs.3.rs-437201/v1
Autor:
Kieren Bradley, Brian Elliott Hayden, Jean-Philippe Soulie, Dave Stanton, Daniel W. Hewak, Chris Vian, Tristan Temple
Publikováno v:
Advanced Optics for Imaging Applications: UV through LWIR IV.
Publikováno v:
J Vis Exp
Budding yeast has been widely used as a model in studying proteins associated with human diseases. Genome-wide genetic screening is a powerful tool commonly used in yeast studies. The expression of a number of neurodegenerative disease-associated pro
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by rapidly progressive degeneration of motor neurons in the brain and spinal cord. Although most forms of ALS are sporadic (sALS), ∼10% of cases are inherited in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9cd981b3469491fee3e47c6c17a6396
https://europepmc.org/articles/PMC5441790/
https://europepmc.org/articles/PMC5441790/
Autor:
Randall Toy, Ruth A. Keri, Aaron T. Mayer, Pubudu M. Peiris, Elizabeth Doolittle, Elliott Hayden, Jenna Pansky, Lisa Bauer, Efstathios Karathanasis, Emily Tran, Erik Schmidt, Mark A. Griswold
Publikováno v:
ACS Nano. 6:4157-4168
While nanoparticles maximize the amount of chemotherapeutic drug in tumors relative to normal tissues, nanoparticle-based drugs are not accessible to the majority of cancer cells because nanoparticles display patchy, near-perivascular accumulation in
Publikováno v:
Evidence-Based Practice; Sep2023, Vol. 26 Issue 9, p22-23, 2p
Publikováno v:
Acta Crystallographica Section A Foundations and Advances. 71:s263-s264
Autor:
Randall Toy, Andrew Camann, Joseph D. Meyers, Elliott Hayden, Pubudu M. Peiris, Efstathios Karathanasis, Hanping Wu, Peter Vicente, Emily Tran, David L. Wilson, Agata A. Exner, Jenna Pansky, Ketan B. Ghaghada, Zachary Berman
Publikováno v:
ACS nano. 7(4)
Tumors present numerous biobarriers to the successful delivery of nanoparticles. Decreased blood flows and high interstitial pressures in tumors dictate the degree of resistance to extravasation of nanoparticles. To understand how a nanoparticle can
Autor:
Ruth A. Keri, Elliott Hayden, Aaron T. Mayer, Jenna Pansky, Randall Toy, Pubudu M. Peiris, Efstathios Karathanasis, Elizabeth Doolittle, Erik Schmidt, Mark A. Griswold, Emily Tran, Lisa Bauer
Publikováno v:
2013 International Workshop on Magnetic Particle Imaging (IWMPI).
Therapeutic efficacy was evaluated by comparing survival times of treated animals with untreated animals and control groups. The mean survival time for animals receiving a single treatment of Drug-NC followed by RF exposure was 25.1 days, compared to